CD133 Inhibitors

CD133, also known as Prominin-1, is a cell surface glycoprotein that has garnered significant attention due to its association with cancer stem cells (CSCs). CSCs are a subpopulation of tumor cells believed to possess self-renewal and differentiation capabilities, contributing to tumor initiation, progression, and recurrence. CD133 Inhibitors represent a class of compounds designed to impede the activity or expression of the CD133 protein, with the overarching goal of disrupting the functions associated with CSCs. These inhibitors typically act through diverse mechanisms, including interference with CD133 signaling pathways, inhibition of CD133 expression, or disruption of CD133 protein interactions. The rationale behind developing CD133 Inhibitors lies in the hypothesis that targeting CSCs, and specifically CD133-positive cells, may hinder tumor growth and reduce the likelihood of cancer recurrence.

CD133 Inhibitors can vary widely, encompassing small molecules, peptides, or antibodies. Small molecules may interact with the CD133 protein directly, altering its conformation or blocking its binding sites. Peptides and antibodies, on the other hand, may specifically recognize and bind to CD133, leading to inhibition of its biological functions. The development and optimization of CD133 Inhibitors are ongoing areas of research, with a focus on enhancing specificity, efficacy, and bioavailability.